Vanderbilt-Ingram Cancer Center researchers included in ASCO annual reportFeb. 5, 2020, 3:05 PM
by Tom Wilemon
Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer.
The annual report, issued by the American Society of Clinical Oncology (ASCO), was published on World Cancer Day, Feb. 4
Leora Horn, MD, Ingram Professor of Cancer Research and clinical director of Thoracic Oncology at VICC, is featured for “First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.”
Brian Rini, MD, Ingram Professor of Cancer Research and chief of Clinical Trials, is featured for “Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinomas.”
Clinical Cancer Advances is an independent annual review of the prior year’s major achievements and emerging trends in clinical cancer research and care. The report highlights current trends in the field and identifies cancer research priorities that have great potential to advance progress against cancer.
The report, now in its 15th edition, is developed by a 20+ member editorial board of experts in a range of cancer types, subspecialties and care issues. The editors reviewed scientific literature published in peer-reviewed journals or presented at major medical conferences, primarily from October 2018 to September 2019, and selected advances that improve meaningful patient outcomes and have a strong scientific impact.
The editors also proposed priority areas of research that address vital unmet needs in cancer care and have the potential to improve the knowledge base for clinical decision-making.